Why Palvella Therapeutics, Inc. (PVLA) stock rose 10.9% on Wednesday, October 28, 2026

Palvella Therapeutics, Inc. (PVLA) closed at $147.47, up 10.95% on Wednesday, October 28, 2026, on volume of 367,915 shares (1.8× its 3-month average); market value about $2.10B.

What happened: primary sources

Events Nexqual found for PVLA on Wednesday, October 28, 2026 or the trading day before (October 27, 2026):

• Oct 28, 2026: SEC 8-K: Other material event source
  Quoted from the filing: “On October 28, 2026, Palvella Therapeutics, Inc. (the " Company ") issued a press release announcing that the U.S. Food and Drug Administration (" FDA ") has accepted for filing and granted Priority Review to the Company's New Drug Application for QTORIN 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations. The FDA has assigned a Prescription Drug User Fee Act target action date of February 28, 2027. A copy of the press release is filed as Exhibit 99.1 to this Current Report on…”
• Oct 28, 2026: Chardan Capital: Maintained, Buy, price target $240

These are listed as context. A filing or rating change on the same day is not proof that it caused the move; read the source.

More on PVLA

PVLA stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. Other big moves that day: October 28, 2026.

Sources: SEC EDGAR, Nexqual Earnings Flash, analyst rating changes, Nexqual market data. Built October 28, 2026 at 22:05 UTC. Not investment advice.

Data source: Nexqual. Last updated: October 28, 2026 at 22:05 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt